About 2,845 results

ALLMedicine™ Ewing Sarcoma Center

Research & Reviews  1,053 results

Fever and Systemic Inflammatory Response Syndrome After Wide Resection of Pediatric Bon...
Journal of Pediatric Orthopedics; Gallaway KE, Atadja LA et. al.

May 14th, 2022 - While postoperative fever is common and thought to be physiological, data is limited in pediatric patients with bone sarcomas. Understanding the predictive value of postoperative fever and systemic inflammatory response syndrome (SIRS) in this pop...

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

May 13th, 2022 - Background: Irinotecan is a prodrug of an inhibitor of topoisomerase 1 (active metabolite is SN-38) with known activity in sarcomas, however it has limitations including suboptimal bioavailability and systemic side effects including severe diarrhe...

Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case.
Journal of Pediatric Hematology/oncology; Müngen E, Yaman Bajin İ et. al.

May 11th, 2022 - Ifosfamide is an important chemotherapeutic agent used in the therapeutic protocols of many malignant tumors. Central nervous system toxicity of ifosfamide manifests with encephalopathy in 10% to 30% of patients treated with ifosfamide. Thiamine a...

New Approaches Promise to Improve Local Ewing Sarcoma Results.
Journal of Pediatric Hematology/oncology; Cohen IJ, Ash S

May 11th, 2022 - The study by Whelan and colleagues showed that addition of busulfan and melphalan conditioning and autologous stem cell rescue to conventional EURO-E.W.I.N.G STUDY chemotherapy in local nonmetastatic Ewing sarcoma improves prognosis. However, almo...

Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Comp...
Journal of Pediatric Hematology/oncology; Zandaki D, Ismael T et. al.

May 11th, 2022 - Interval compression (IC), a regimen of alternating vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide every 2 weeks, improves survival for localized Ewing sarcoma (ES), with uncertain effect on metastatic disease. We reviewed the c...

see more →

Guidelines  5 results

Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Li...
Orthopaedics & Traumatology, Surgery & Research : OTSR; Gomez-Brouchet A, Mascard E et. al.

Apr 10th, 2019 - Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Co...

Practical recommendations for fertility preservation in women by the FertiPROTEKT netwo...
Archives of Gynecology and Obstetrics; Schüring AN, Fehm T et. al.

Nov 28th, 2017 - Most guidelines about fertility preservation are predominantly focused on scientific evidence, but are less practically orientated. Therefore, practically oriented recommendations are needed to support the clinician in daily practice. A selective ...

ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas.
Annals of Oncology : Official Journal of the European Soc... Wilhelm M, Dirksen U et. al.

Jun 26th, 2014 - Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct challenges upon cancer care services, many reporting feeling marginalized and their needs n...

Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the ...
Pediatric Blood & Cancer; Meyer JS, Nadel HR et. al.

May 6th, 2008 - The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standar...

Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ®)–Health Professional Version
National Cancer Institute

Dramatic improvements in survival have been achieved for children and adolescents with cancer.[1] Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[1] For Ewing sarcoma, the 5-year survival rate has increased from 59% t...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  24 results

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

May 13th, 2022 - Background: Irinotecan is a prodrug of an inhibitor of topoisomerase 1 (active metabolite is SN-38) with known activity in sarcomas, however it has limitations including suboptimal bioavailability and systemic side effects including severe diarrhe...

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma or Ewing-Like Sarcoma

Apr 28th, 2022 - The purpose of this study is to find out whether LY2880070 combined with the chemotherapy drug gemcitabine is an effective treatment for Ewing sarcoma or Ewing-like sarcoma.

A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

Apr 4th, 2022 - METHODOLOGY: Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind placebo-controlled trial, with 5 cohorts: cohort A: Osteosarcoma, cohort B: Ewing sarcoma, cohort C: Chondrosarcoma, cohort D : chondroma, cohort E: ...

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Mar 29th, 2022 - Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcri...

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

Feb 16th, 2022 - 3 independent, multicenter, prospective, signel-arm phase II trial, based on 2-stage Simon's optimal design, will be conducted in parallel to assess the efficacy of pembrolizumab + cabozantinib, in distinct populations of sarcomas: stratum 1: adva...

see more →

News  41 results

Devimistat Plus Hydroxychloroquine Shows Early Promise in Relapsed Clear Cell Sarcoma

Jan 7th, 2022 - No dose-limiting toxicities (DLTs) have been reported in the first cohort of patients with relapsed clear cell sarcoma who received the combination of devimistat (CPI-613) and hydroxychloroquine in the dose-escalation portion of the ongoing phase ...

ONCT-216 Shows Encouraging Efficacy, Safety in Relapsed/Refractory Ewing Sarcoma

Nov 24th, 2021 - The targeted small molecule inhibitor of the E26 transformation-specific family of oncoproteins, ONCT-216 (formerly TK216), produced notable response and disease control rates when delivered at the recommended phase 2 dose (RP2D) to heavily pretre...

Demetri's Team Approach Translates Into Success in Sarcoma Research

Oct 6th, 2021 - George D. Demetri, MD For some cancer researchers, success means running your own laboratory independent of others, who might be viewed as competitors. Others, like George D. Demetri, MD, find success pursuing a career as a translational and clin...

Dr. Federman on Ongoing Research in Rare Bone and Soft Tissue Sarcoma

Oct 6th, 2021 - Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma. Current research at UCLA’s Jonnson Comprehensive Cancer Ce...

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

see more →

Patient Education  7 results see all →